Premium
Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium
Author(s) -
Ramael Marc,
Lemmens Greet,
Eerdekens Christa,
Buysse Corinne,
Deblier Ivo,
Jacobs Werner,
Van Marck Eric
Publication year - 1992
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.1711680406
Subject(s) - mesothelium , mesothelioma , pathology , immunohistochemistry , cancer research , medicine , chemistry , mesothelial cell
The presence of p53 protein in non‐neoplastic pleural mesothelium (40 cases) and in human malignant mesothelioma (36 cases) was assessed immunohistochemically using the antibodies DO7, CM‐1 and PAb240. In a quarter of the malignant mesotheliomas, there was nuclear immunoreactivity for p53 protein with both the DO7 and CM‐1 antibodies. There were no statistically significant differences between the various mesothelioma subtypes ( P >0·05). No immunoreactivity was found with the PAb240 antibody, suggesting absence of mutant‐type p53 protein. Non‐ neoplastic mesothelium was not immunoreactive with any of the antibodies. We conclude that there is immunoreactivity for p53 protein in some mesotheliomas. p53 protein immunoreactivity could be used to discriminate between neoplastic and reactive mesothelium.